|
 |
Noms commerciaux |
|
|
Les noms commerciaux sont donnés à titre indicatif et la composition en excipients peut être différente selon les pays et selon les laboratoires
|
|
Camtoop |
Mexique |
|
Cantop |
Inde |
|
Hycamtin |
Allemagne, Arabie Saoudite, Australie, Autriche, Belgique, Brésil, Canada, Chili, Colombie, Croatie, Danemark, Egypte, Emirats Arabes Unis , Espagne, Etats Unis d’Amérique, Finlande, France, Grande Bretagne, Grèce, Hongrie, Irlande, Islande, Italie, Japon, Luxembourg, Malaisie, Norvège, Pays bas, Pologne, Portugal, Roumanie, Suède, Suisse, Turquie, Vénézuela |
|
Oncotecan |
Colombie, Equateur |
|
Potactasol |
Allemagne, Argentine, Belgique, Croatie, Finlande, Hongrie, Irlande, Italie, Norvège, Roumanie, Slovénie |
|
Topodria |
Colombie |
|
Topokebir |
Argentine |
|
Topotecan |
Allemagne, Argentine, Belgique, Brésil, Canada, Chili, Colombie, Croatie, Espagne, Finlande, France, Grande Bretagne, Hongrie, Irlande, Italie, Norvège, Pérou, Roumanie, Suède, Suisse |
|
Topotel |
Egypte |
|
Toranex |
Mexique |
|
Tpopoxin |
Turquie |
|
|
 |
 |
Bibliographie : Topotecan |
|
|
Type |
Source |
| 753 |
Laboratoire |
Topotecan (Topotecan Medac®) - Summary of Product Characteristics
Medac 2016 |
| 823 |
Revue |
Patel K, Craig SB, McBride MG, Palepu NR.
Microbial inhibitory properties and stability of topotecan hydrochloride injection.
Am J Health-Syst Pharm 1998 ; 55: 1584-1587. |
| 1026 |
Revue |
Mayron D, Gennaro AR.
Stability and compatibility of topotecan hydrochloride with selected drugs.
Am J Health-Syst Pharm 1999 ; 56: 875-881. |
| 1075 |
Revue |
Craig SB, Bhatt UH, Patel K.
Stability and compatibility of topotecan hydrochloride for injection with common infusion solutions and containers.
J Pharm Biomed Anal 1997 ; 16: 199-205. |
| 1274 |
Revue |
Krämer I, Thiesen J.
Pharmazeutische aspekte von topotecan-infusionen.
TAP Pharmazeutische Zeitung 1997 ; 31: 30-33. |
| 1423 |
Revue |
Trissel LA, Martinez JF, Gilbert DL.
Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 514-518. |
| 1425 |
Revue |
Krämer I, Thiesen J.
Stability of topotecan infusion solutions in polyvinylchloride bags and elastomeric portable infusion devices.
J Oncol Pharm Practice 1999 ; 5: 75-82. |
| 1662 |
Revue |
Trissel LA, Saenz CA, Ingram DS, Ogundele AB.
Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs.
J Oncol Pharm Practice 2002 ; 8: 33-37. |
| 1953 |
Revue |
Trissel LA, Saenz CA, Ogundele AB, Ingram DS.
Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2004 ; 61: 2289-2293. |
| 1976 |
Revue |
Trissel LA, Xu QA.
Physical and chemical stability of palonosetron hydrochloride with topotecan hydrochloride and irinotecan hydrochloride during simulated Y-site administration.
Int J Pharm Compound 2005 ; 9, 3: 238-241. |
| 5157 |
Revue |
Bello W, Hosotte C, Stampfli C, Pierrot A, Munier F L, Berger-Gryllaki M, Pezzatti J, Carrez L, Sadeghipour F.
Stability study of topotecan in ophthalmic prefilled syringes for intravitreal delivery
EJHP 2025 33:67-72 |
|
|
